首页> 外文OA文献 >Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol
【2h】

Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol

机译:通过在单一增压方案中使用水泡性口炎病毒和改良的痘苗病毒安卡拉疫苗载体高效控制猕猴中的艾滋病病毒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Previous studies have shown that vaccination and boosting of rhesus macaques with attenuated vesicular stomatitis virus (VSV) vectors encoding Env and Gag proteins of simian immunodeficiency virus-human immunodeficiency virus (SHIV) hybrid viruses protect rhesus macaques from AIDS after challenge with the highly pathogenic SHIV 89.6P (23). In the present study, we compared the effectiveness of a single prime-boost protocol consisting of VSV vectors expressing SHIV Env, Gag, and Pol proteins to that of a protocol consisting of a VSV vector prime followed with a single boost with modified vaccinia virus Ankara (MVA) expressing the same SHIV proteins. After challenge with SHIV 89.6P, MVA-boosted animals controlled peak challenge viral loads to less than 2 × 106 copies/ml (a level significantly lower than that seen with VSV-boosted animals and lower than those reported for other vaccine studies employing the same challenge). MVA-boosted animals have shown excellent preservation of CD4+ T cells, while two of four VSV-boosted animals have shown significant loss of CD4+ T cells. The improved protection in MVA-boosted animals correlates with trends toward stronger prechallenge CD8+-T-cell responses to SHIV antigens and stronger postchallenge SHIV-neutralizing antibody production.
机译:先前的研究表明,用猿猴免疫缺陷病毒-人类免疫缺陷病毒(SHIV)混合病毒的Env和Gag蛋白的减毒水疱性口炎病毒(VSV)载体接种和加强恒河猴猕猴,可以抵抗高致病性SHIV后保护猕猴免受艾滋病侵害89.6P(23)。在本研究中,我们比较了由表达SHIV Env,Gag和Pol蛋白的VSV载体组成的单一初免-增强方案与由VSV载体prime加上经修饰的痘苗病毒安卡拉进行单次增强的协议的有效性(MVA)表达相同的SHIV蛋白。在用SHIV 89.6P攻击后,MVA增强的动物将峰值挑战病毒载量控制在2×106拷贝/毫升以下(水平明显低于VSV增强的动物,但低于其他使用相同疫苗的疫苗研究报告的水平)挑战)。 MVA增强动物表现出出色的CD4 + T细胞保存能力,而四只VSV增强动物表现出两只CD4 + T细胞明显丧失。 MVA增强动物的保护作用增强与攻击前针对SHIV抗原的CD8 + -T细胞应答增强以及攻击后SHIV中和抗体产生更强的趋势相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号